Immunomodulatory Therapies for Recurrent Pregnancy Loss: Mechanisms, Evidence, and Clinical Applications

Abstract

Recurrent pregnancy loss (RPL) remains a challenging clinical entity with multifactorial etiologies, including immunological dysfunctions that impact maternal-fetal tolerance. Immunomodulatory therapies have emerged as a promising avenue for women experiencing unexplained RPL, with interventions ranging from corticosteroids to intravenous immunoglobulin (IVIG), low molecular weight heparin (LMWH), and newer biologics. This review synthesizes current evidence, elucidates the mechanistic rationale for immunomodulation in RPL, and provides practical guidance for clinicians navigating this complex therapeutic landscape.

Introduction

Recurrent pregnancy loss, typically defined as two or more consecutive pregnancy losses before 20 weeks gestation, affects approximately 1–2% of reproductive-age women. The psychological and emotional impact on affected couples is profound, and the quest for effective treatments remains a high priority in reproductive medicine. While anatomical, genetic, endocrine, and thrombotic causes account for a subset of cases, immune dysregulation is increasingly recognized as a pivotal contributor in unexplained RPL. Understanding the immunopathogenesis of RPL has led to the development and application of immunomodulatory therapies aimed at restoring immune tolerance and improving pregnancy outcomes.

Epidemiology / Disease Burden

RPL poses a significant public health burden, with estimates suggesting that up to 5% of women attempting conception will experience two or more losses. Epidemiological studies highlight a higher prevalence among women with advanced maternal age, and the risk increases with the number of prior losses. The direct and indirect costs, including medical interventions, psychological care, and societal implications, underscore the importance of advancing effective prevention and management strategies.

Pathophysiology

The immunological paradigm of RPL centers on the delicate balance required for successful maternal-fetal immune tolerance. Breakdown in this balance, whether due to aberrant natural killer (NK) cell activity, dysregulated T-helper (Th) cell responses, or the presence of antiphospholipid antibodies, can result in fetal rejection. Elevated Th1/Th2 cell ratios, increased NK cell cytotoxicity, and impaired regulatory T-cell (Treg) function have all been implicated. Molecular studies reveal that abnormal cytokine profiles and defective expression of immune checkpoint molecules like HLA-G may further disrupt implantation and placental development.

Risk Factors

Risk factors for immunologically mediated RPL include a history of autoimmune disorders (e.g., systemic lupus erythematosus, antiphospholipid syndrome), elevated NK cell activity, and the presence of specific genetic polymorphisms affecting immune regulation. Environmental influences such as chronic stress and infections may exacerbate immune dysfunction. Other established risk factors include advanced maternal age, obesity, and prior obstetric complications. Identification of these factors is critical for tailoring individualized management plans.

Clinical Features

RPL typically presents as two or more consecutive miscarriages, often in the first trimester. While many women are asymptomatic between losses, some may exhibit features suggestive of underlying immune pathology, such as a history of autoimmune conditions, thrombosis, or pregnancy morbidities like preeclampsia. Detailed clinical evaluation, including personal and family history, can yield vital clues to underlying immunological contributions.

Diagnosis

Standard diagnostic workup for RPL encompasses anatomical imaging, parental karyotyping, hormonal evaluation, and screening for thrombophilia. Immunological assessment includes testing for antiphospholipid antibodies, antinuclear antibodies, and, in select cases, peripheral NK cell quantification or functional assays. However, the clinical utility of many immune tests remains debated, and guidelines emphasize the need for judicious interpretation in the context of clinical findings.

Treatment & Management

Management strategies for RPL are tailored according to identified etiologies. For women with confirmed antiphospholipid syndrome, combination therapy with low-dose aspirin and LMWH is well-established. In cases with suspected immune-mediated RPL but without clear autoimmune disease, empirical immunomodulatory therapies are considered. Corticosteroids have been used to suppress aberrant immune responses, but concerns about side effects and inconsistent efficacy temper their routine use. IVIG has shown promise in select populations, particularly those with elevated NK cell activity or secondary autoimmune features, but evidence remains mixed. LMWH may confer benefit beyond its anticoagulant effects by modulating trophoblast invasion and immune interactions at the maternal-fetal interface. Other interventions, such as intralipid infusions and paternal leukocyte immunization, are less well-supported and remain investigational.

Recent Advances / Emerging Therapies

Recent research has focused on targeted biologic therapies, including tumor necrosis factor-alpha (TNF-α) inhibitors and agents modulating Treg cell function. Early-phase studies of TNF-α inhibitors, such as etanercept and adalimumab, suggest potential benefit in women with refractory RPL, though large-scale trials are lacking. Granulocyte colony-stimulating factor (G-CSF) has also been investigated for its ability to enhance endometrial receptivity and immune tolerance, with preliminary data supporting improved pregnancy outcomes. Advances in reproductive immunology have spurred interest in monoclonal antibodies targeting specific immune checkpoints, though these remain experimental. Personalized approaches, leveraging immune profiling to direct therapy, represent a promising future direction.

Guideline Recommendations

Major guidelines, including those from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE), recommend etiologic evaluation and evidence-based management. For RPL associated with antiphospholipid antibody syndrome, aspirin and LMWH are standard of care. The use of empirical immunomodulatory therapies in unexplained RPL is not routinely recommended outside of clinical trials, given inconsistent evidence and potential risks. Multidisciplinary collaboration and individualized patient counseling are emphasized, with ongoing research needed to clarify the role of newer biologics and precision immunotherapies.

Conclusion

Immunomodulatory therapies for recurrent pregnancy loss represent an evolving field bridging immunology and reproductive medicine. While significant progress has been made in elucidating mechanisms and developing targeted interventions, robust clinical evidence remains limited for many therapies. Personalized, evidence-based care—guided by ongoing research and multidisciplinary expertise—remains the cornerstone for optimizing outcomes in women with RPL. Future advances in immune profiling and biologic therapeutics hold promise for addressing this complex and emotionally devastating condition.